Thanks are due to you for this letter and we would like to respond regarding some questions raised about our meta-analysis.

In this letter, the authors questioned the index used in the meta-analysis and recommended hazard ratio (HR) instead of relative risk (RR) \[[@B1]\]. HR is truly a good index for survival analysis of one disease because it considers the effects of time and it worked when extracting data from studies we selected; however, RR is appropriate for comparing the control group and treatment group (NAs group) here, as it has equal effects to OR.

The total number of patients was the same only in 1-year and 3-year recurrence, but, in OS and DFS, the numbers were different \[[@B2]\].

Disease-free survival has been defined as no recurrence of HCC in our article \[[@B2]\].

Randomized trials were really what we wanted to study in our meta-analysis; however, due to a lack of enough studies and data, this was unfortunately not possible \[[@B2]\].

We are not sure if postoperative NAs therapy has no impact on patients\' short-term survival, for the reason that HBV reactivation usually occurs one month after operations were performed \[[@B3]\], so that is why we performed this meta-analysis. And as our results show, we do not agree with the comment that NAs have no short-term effects on survival and recurrence \[[@B1]\].

We would like to thank again the authors for this valuable letter and also for their concerns. We would like to receive further suggestions on our study.
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